Dan Mulreany's Colleagues at QED Therapeutics
Dan Mulreany's Contact Details
HQ
650-231-4088
650-231-4088
Location
Company
QED Therapeutics
QED Therapeutics
Dan Mulreany's Company Details
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
Frequently Asked Questions about Dan Mulreany
Dan Mulreany currently works for QED Therapeutics.
Dan Mulreany's role at QED Therapeutics is director, business development and operations.
Dan Mulreany's email address is ***@qedtx.com. To view Dan Mulreany's full email address, please signup to ConnectPlex.
Dan Mulreany works in the Biotechnology industry.
Dan Mulreany's colleagues at QED Therapeutics are Robyn Leary, Greg Troupe, Terry Cho, Hiywot MS, Devendra A., Timothy Bisson, Quinn Nazarewycz and others.
Dan Mulreany's phone number is ["+17039890841"]